Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Spartrapon Jun 22, 2020 2:05pm

131 Views

Post# 31177458

RE:RE:RE:RE:RE:RE:Not sure what's new?

That's exactly what poster #4335 hints at:

Sortilin receptor is associated with VM and it is needed for VM formation in TNBC (MDA-MB-231) and ovarian (ES-2) cancer cells.
Both doxorubicin (TH1904) and docetaxel (TH1902) conjugates strongly inhibit formation of VM 3D-tubular structures indicating that these new
chemical entities have different anticancer properties than their parent drugs.
Docetaxel and doxorubicin affects the VM structure only at concentrations higher than the ones tolerated in patients
Overall, results indicate that sortilin regulates VM, and that exploiting sortilin’s functions to increase drug internalization may complement current
treatments in patients with TNBC or ovarian cancer and may bypass some resistance mechanism of cancer cells.

jfm1330 wrote: If it's the case it would change the whole ball game, because if so, you would have a double anti-cancer effect, one from the introduction of a cytotoxic drug into the cancer cell, but also another effect from the peptide itself inhibiting the VM process of the tumor by interacting with the Sortilin receptors on the membrane of the cells. So it would be a double effect. Is it really the case or the IR person was just overoptimistic.

SPCEO1 wrote:

Our new data demonstrate that sortilin is a key player in the formation of VM structure - silencing sortilin stops the formation of the VM structure for both ovarian and TNBC cancer cells.